Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182748 | PMC |
| http://dx.doi.org/10.1016/j.micpath.2020.104228 | DOI Listing |
Publication Analysis
Top Keywords
hydroxychloroquine azithromycin
8
vitro testing
4
testing combined
4
combined hydroxychloroquine
4
azithromycin sars-cov-2
4
sars-cov-2 synergistic
4
synergistic human
4
human coronaviruses
4
coronaviruses sars-cov-2
4
sars-cov-2 appeared
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!